Recent stock performance and business context

CRISPR Therapeutics (CRSP) has drawn attention after a recent pullback, with the stock closing at US$49.80 and showing mixed returns over different time frames that may prompt investors to reassess the story.

Over the past day the stock declined 0.9%, over the past week it fell 3.9%, and over the past month it declined 5.6%. Looking back over the past 3 months, the share price is up 2.2%, while the year to date move is a decline of 7.4%.

For longer term holders, the 1 year total return is 20.4%, while the 3 year total return shows a decline of 13.8% and the 5 year total return is down 61.0%. These mixed performance figures set the backdrop for evaluating the company today.

At around US$49.80 per share, CRISPR Therapeutics has seen short term share price pressure recently, even as its 1 year total shareholder return of 20.4% contrasts with weaker multi year outcomes. This may reflect shifting views on its risk profile.

If this kind of volatility has your attention, it can be a useful moment to see what else is moving in related areas, starting with 40 healthcare AI stocks.

With CRISPR Therapeutics reporting strong annual revenue and net income growth but still posting a loss of US$568.534 million, is the recent pullback a chance to invest, or is the market already pricing in future growth?

Preferred Price to Book of 2.6x: Is it justified?

CRISPR Therapeutics is currently described as good value relative to peers, yet expensive compared to the broader US biotechs industry based on its P/B of 2.6x. That split verdict gives you two different reference points for assessing the recent share price pullback.

P/B compares the market value of the company to its accounting book value, which can be a useful cross check for early stage or unprofitable biotechs where earnings are not yet a reliable anchor. For CRISPR Therapeutics, the P/B of 2.6x sits well below a peer average of 7.1x. This suggests the stock is priced at a lower premium to its balance sheet than closer comparables, even though it is still described as expensive relative to the broader US biotechs industry average of 2.4x.

This mix of cheaper than direct peers but slightly richer than the wider industry indicates the market appears to be assigning some value to the company’s gene editing portfolio, while still keeping a discount versus closer comparables. Without a fair ratio estimate, there is no additional model based reference level to indicate where that multiple might gravitate over time.

Result: Price to book of 2.6x (ABOUT RIGHT)

However, investors still face clear risks, including ongoing losses of US$568.534 million and uncertainty around clinical progress across the gene editing pipeline.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another view using our DCF model

The earlier P/B comparison suggested CRISPR Therapeutics is roughly in line with broader biotech, but our DCF model presents a sharper contrast. On this approach, the stock at US$49.80 is described as trading about 72.6% below an estimated value of US$181.58, which highlights a wide gap for you to interpret.

If two methods point in different directions like this, it often comes down to which inputs you consider more reliable, the balance-sheet-based multiple or the cash flow assumptions behind the model, and whether that gap reflects risk, opportunity, or a combination of both.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation models and a balance of risks and rewards, sentiment on CRISPR Therapeutics is clearly split. It helps to move quickly, review the data in detail, and form your own stance using the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If CRISPR Therapeutics has sharpened your focus, do not stop here. Broaden your watchlist with targeted stock ideas that match your goals and risk comfort.

• Target potential value opportunities by scanning 44 high quality undervalued stocks that combine quality fundamentals with prices that may look interesting.
• Strengthen your income focus by checking 8 dividend fortresses that offer higher yields with an emphasis on resilience.
• Prioritise durability by reviewing 70 resilient stocks with low risk scores designed to highlight stocks with more modest risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.